Australian Broker Call *Extra* Edition – Jun 07, 2023

This story features ADAIRS LIMITED, and other companies. For more info SHARE ANALYSIS: ADH

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

ADH (3)   GDA   IPD   IPH   MGV   MVF   NXD   PDN   PLY   PPE   TLX   VIT  

ADH    ADAIRS LIMITED

Furniture & Renovation – Overnight Price: $1.50

Canaccord Genuity rates ((ADH)) as Hold (3) –

Canaccord Genuity observes cost inefficiencies and the recent slowdown in sales are playing havoc with Adairs' earnings, with EBIT now -21% lower than the mid point of management's forecasts back in August 2022. Margin pressure is expected to continue into FY24.

The broker understands the trading environment both in stores and online has weakened since April and early indications from typical end-of-financial-year sales have been disappointing. Canaccord Genuity retains a Hold rating and reduces the target to $1.60 from $2.40.

This report was published on June 5, 2023.

Target price is $1.60 Current Price is $1.50 Difference: $0.1
If ADH meets the Canaccord Genuity target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $1.72, suggesting upside of 14.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 16.00 cents and EPS of 24.00 cents.
At the last closing share price the estimated dividend yield is 10.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.25.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 22.2, implying annual growth of -15.8%.
Current consensus DPS estimate is 14.3, implying a prospective dividend yield of 9.5%.
Current consensus EPS estimate suggests the PER is 6.8.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 13.00 cents and EPS of 19.00 cents.
At the last closing share price the estimated dividend yield is 8.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.89.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 19.2, implying annual growth of -13.5%.
Current consensus DPS estimate is 14.0, implying a prospective dividend yield of 9.3%.
Current consensus EPS estimate suggests the PER is 7.8.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Goldman Sachs rates ((ADH)) as Neutral (3) –

Goldman Sachs updates estimates following the revised guidance from Adairs. The broker's estimates are at the mid-point of revenue guidance of $616-622m and at the lower end of EBIT guidance ($62-65m) as margin headwinds are expected to increase.

On a relative basis Goldman Sachs believes the core business is resilient, supported by a strong loyalty base but remains cautious about the outlook for Focus and Mocka.

Subdued trading is expected to continue into FY24. Neutral rating retained. Target is reduced -14.8% to $2.30.

This report was published on June 4, 2023.

Target price is $2.30 Current Price is $1.50 Difference: $0.8
If ADH meets the Goldman Sachs target it will return approximately 53% (excluding dividends, fees and charges).
Current consensus price target is $1.72, suggesting upside of 14.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 13.00 cents and EPS of 23.00 cents.
At the last closing share price the estimated dividend yield is 8.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.52.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 22.2, implying annual growth of -15.8%.
Current consensus DPS estimate is 14.3, implying a prospective dividend yield of 9.5%.
Current consensus EPS estimate suggests the PER is 6.8.

Forecast for FY24:

Goldman Sachs forecasts a full year FY24 dividend of 15.00 cents and EPS of 25.00 cents.
At the last closing share price the estimated dividend yield is 10.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 19.2, implying annual growth of -13.5%.
Current consensus DPS estimate is 14.0, implying a prospective dividend yield of 9.3%.
Current consensus EPS estimate suggests the PER is 7.8.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Wilsons rates ((ADH)) as Market Weight (3) –

Adairs has now downgraded FY23 earnings (EBIT) expectations twice since issuing original guidance in August 2022, observes Wilsons.

This time, management lowered sales and earnings guidance by -4% and -15.3%, respectively.

The analysts point out sales visibility has become more tricky to forecast, particularly given Focus is newly acquired and solutions are unproven for Mocka. Moreover, it's thought costs remain an issue at the distribution centre.

More positively, 2H gross margins were largely retained and inventory levels are reflecting Adairs typical cycle, explains the broker.

The target is lowered to $1.60 from $2.40 and the Market Weight rating is kept.

This report was published on June 5, 2023.

Target price is $1.60 Current Price is $1.50 Difference: $0.1
If ADH meets the Wilsons target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $1.72, suggesting upside of 14.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 14.00 cents and EPS of 22.40 cents.
At the last closing share price the estimated dividend yield is 9.33%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.70.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 22.2, implying annual growth of -15.8%.
Current consensus DPS estimate is 14.3, implying a prospective dividend yield of 9.5%.
Current consensus EPS estimate suggests the PER is 6.8.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 16.00 cents and EPS of 24.60 cents.
At the last closing share price the estimated dividend yield is 10.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.10.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 19.2, implying annual growth of -13.5%.
Current consensus DPS estimate is 14.0, implying a prospective dividend yield of 9.3%.
Current consensus EPS estimate suggests the PER is 7.8.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

GDA    GOOD DRINKS AUSTRALIA LIMITED

Food, Beverages & Tobacco – Overnight Price: $0.56

Petra Capital rates ((GDA)) as Downgrade to Hold from Buy (3) –

Good Drinks Australia should return to earnings growth in FY24 as freight costs assume more normal levels and pricing improves while marketing costs are reined in, Petra Capital assesses.

The company has sold 15 gaming licenses, raising $4.9m in cash and the proceeds will fund the bulk of the development of Joe's Waterhole into Matso's Sunshine Coast. The company now expects FY23 EBITDA to be flat.

While attrracted to the growth story as Good Drinks gains market share and replaces contracted product with branded product, the broker highlights the competitive the industry and difficulty in gaining sufficient scale.

Valuation metrics on revised forecasts appear full and the rating is downgraded to Hold from Buy. Target is reduced -24% to $0.63.

This report was published on June 1, 2023.

Target price is $0.63 Current Price is $0.56 Difference: $0.075
If GDA meets the Petra Capital target it will return approximately 14% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Petra Capital forecasts a full year FY23 dividend of 0.00 cents and EPS of 0.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 79.29.

Forecast for FY24:

Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 26.43.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

IPD    IMPEDIMED LIMITED

Medical Equipment & Devices – Overnight Price: $0.15

Wilsons rates ((IPD)) as Overweight (1) –

Wilsons highlights the news that Florida Blue, original payor under Blue Cross Blue Shield, will be the second private payor to change its policy to include Bioimpedance Spectroscopy as medically necessary, referencing ImpediMed's L-Dex technology.

The broker flags this as important as BCBS is one of the largest private payors in the US and this will likely impel the rest of the payor market to have a view on the use of the technology in lymphoedema. Overweight rating and 21c target maintained.

This report was published on June 5, 2023.

Target price is $0.21 Current Price is $0.15 Difference: $0.055
If IPD meets the Wilsons target it will return approximately 35% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 1.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 14.09.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 0.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.22.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

IPH    IPH LIMITED

Legal – Overnight Price: $7.72

Petra Capital rates ((IPH)) as Buy (1) –

Petra Capital has analysed monthly data for April, using patent filings as a measure of market share. The broker emphasises, in the case of IPH, this analysis is only relevant for its Australian operations.

Filings were well down in April, year-on-year, and the key will be May and June, which are seasonally larger months. Still, the broker continues to believe the core business and growth prospects are intact. Buy rating and $10.65 target maintained.

This report was published on June 2, 2023.

Target price is $10.65 Current Price is $7.72 Difference: $2.93
If IPH meets the Petra Capital target it will return approximately 38% (excluding dividends, fees and charges).
Current consensus price target is $10.74, suggesting upside of 39.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Petra Capital forecasts a full year FY23 dividend of 33.20 cents and EPS of 43.10 cents.
At the last closing share price the estimated dividend yield is 4.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.91.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 42.8, implying annual growth of 77.7%.
Current consensus DPS estimate is 31.7, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 18.0.

Forecast for FY24:

Petra Capital forecasts a full year FY24 dividend of 34.30 cents and EPS of 45.10 cents.
At the last closing share price the estimated dividend yield is 4.44%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.12.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 44.9, implying annual growth of 4.9%.
Current consensus DPS estimate is 33.0, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 17.2.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MGV    MUSGRAVE MINERALS LIMITED

Gold & Silver – Overnight Price: $0.30

Canaccord Genuity rates ((MGV)) as Speculative Buy (1) –

Musgrave Minerals has published a stage 1 prefeasibility study for the Cue gold project in Western Australia. Canaccord Genuity observes the company has optimised the lower-risk portions of the resource, enabling higher-grade material to largely be mined from open pit sources.

Given the strategic nature of the project, the broker suspects a number of the company's neighbours would benefit from owning the project as there are two mills within 4 km.  A weighted takeover scenario continues to be modelled and the broker retains a Speculative Buy rating with a $0.50 target.

This report was published on June 5, 2023.

Target price is $0.50 Current Price is $0.30 Difference: $0.2
If MGV meets the Canaccord Genuity target it will return approximately 67% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents and EPS of 0.00 cents.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 30.00.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MVF    MONASH IVF GROUP LIMITED

Healthcare services – Overnight Price: $1.17

Wilsons rates ((MVF)) as Initiation of coverage with Overweight (1) –

Wilsons initiates coverage on Monash IVF, the second-largest provider of assisted reproductive services in Australia, with an Overweight rating and $1.35 target.

Contrary to consensus expectations, which assume another 12 months of contraction, the analysts believe stimulated cycle volumes have rebased higher. Also, it's felt the company's SE Asian business is underrated.

Moreover, independent of fertility, national reimbursement for pre-conception genetic carrier screening boosts the industry’s diagnostic revenues, and opens up a new volume channel, explains the broker.

Finally, across Wilsons coverage of the Healthcare sector, Monash IVF has the highest free cash flow yield.

This report was published on June 5, 2023.

Target price is $1.35 Current Price is $1.17 Difference: $0.18
If MVF meets the Wilsons target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $1.36, suggesting upside of 16.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 4.60 cents and EPS of 6.60 cents.
At the last closing share price the estimated dividend yield is 3.93%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.73.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 6.2, implying annual growth of 31.4%.
Current consensus DPS estimate is 4.5, implying a prospective dividend yield of 3.8%.
Current consensus EPS estimate suggests the PER is 18.9.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 5.30 cents and EPS of 7.50 cents.
At the last closing share price the estimated dividend yield is 4.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.60.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 7.2, implying annual growth of 16.1%.
Current consensus DPS estimate is 5.1, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 16.2.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NXD    NEXTED GROUP LIMITED

Overnight Price: $1.59

Petra Capital rates ((NXD)) as Buy (1) –

Petra Capital notes a positive performance in ELICOS student arrivals during March, a leading indicator for enrolments. This is particularly significant for Greenwich English, which is NextEd Group's largest division.

Although ABS data indicates a consistent increase in international enrolments, the broker points out there is uncertainty regarding the length of time growth can be sustained at such rates.

The broker expects a strong FY24 before organic growth settles to more normal rates in FY25. Buy rating retained. Target is raised to $1.95 from $1.88.

This report was published on June 2, 2023.

Target price is $1.95 Current Price is $1.59 Difference: $0.36
If NXD meets the Petra Capital target it will return approximately 23% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Petra Capital forecasts a full year FY23 dividend of 0.00 cents and EPS of 2.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 75.71.

Forecast for FY24:

Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of 5.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 28.91.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PDN    PALADIN ENERGY LIMITED

Uranium – Overnight Price: $0.65

Canaccord Genuity rates ((PDN)) as Buy (1) –

The Namibian government has now issued a media statement to clarify some of the perceptions regarding taking a stake in mineral developments. The government has stated it has no intention to seize any stake of existing mineral or petroleum licence holders.

Yet it could seek an equity share in developments from any licences that may be issued in future.

With the spot uranium price exceeding US$55/lb and the likelihood of sustained term market activity in the second half of 2023, Paladin Energy remains a "stand-out Buy", in the broker's opinion. The $1.15 target price is retained.

This report was published on June 5, 2023.

Target price is $1.15 Current Price is $0.65 Difference: $0.5
If PDN meets the Canaccord Genuity target it will return approximately 77% (excluding dividends, fees and charges).
Current consensus price target is $1.10, suggesting upside of 68.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 0.89 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 73.03.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -3.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 1.48 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 43.83.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 1.5, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 43.3.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PLY    PLAYSIDE STUDIOS LIMITED

Gaming – Overnight Price: $0.38

Canaccord Genuity rates ((PLY)) as Buy (1) –

PlaySide Studios has updated on its work-for-hire contracts, noting thee current forward order book is $28.6m. Assuming the company is managing around seven major contracts, Canaccord Genuity observes it now has an average annual contract value of more than $4m.

PlaySide Publishing has announced its first deal with Rocket Flair Studios, with the game set to soft launch through early access in 2024 and make full commercial launch in 2025.

The broker observes a number of milestones over the next couple of years and assesses the stock is trading at compressed multiples despite the de-risked, high-margin WFH division. Buy rating and $0.70 target maintained.

This report was published on June 1, 2023.

Target price is $0.70 Current Price is $0.38 Difference: $0.32
If PLY meets the Canaccord Genuity target it will return approximately 84% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 EPS of minus 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 38.00.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 EPS of 0.00 cents.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PPE    PEOPLEIN LIMITED

Jobs & Skilled Labour Services – Overnight Price: $2.60

Petra Capital rates ((PPE)) as Buy (1) –

PeopleIN has concluded that maximising shareholder value is best served by continuing to execute its existing three-year strategic plan. The focus will be on those sectors with long-term demand for staffing, cross-selling between brands and international recruitment.

Petra Capital suspects selling the company to another party was one of the options considered in the review, and the fact this has not occurred signals relevant parties were unable to reach an agreed value.

Management has confirmed FY23 EBITDA guidance of $62-66m. The broker reiterates a Buy rating and reduces the target to $4.90 from $5.20.

This report was published on June 1, 2023.

Target price is $4.90 Current Price is $2.60 Difference: $2.3
If PPE meets the Petra Capital target it will return approximately 88% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Petra Capital forecasts a full year FY23 dividend of 14.50 cents and EPS of 37.50 cents.
At the last closing share price the estimated dividend yield is 5.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.93.

Forecast for FY24:

Petra Capital forecasts a full year FY24 dividend of 16.00 cents and EPS of 41.00 cents.
At the last closing share price the estimated dividend yield is 6.15%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.34.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

TLX    TELIX PHARMACEUTICALS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $11.02

Wilsons rates ((TLX)) as Overweight (1) –

Wilsons raises its price target for the fourth time this year for Telix Pharmaceuticals to $13 from $10.71.

The broker's FY23 and FY24 forecasts rise to reflect Illuccix share gains, as well as underlying prostate-specific membrane antigen (PSMA) market growth and pricing.

The analysts also increase the FY25 sales forecast by 5.7% after raising the market entry pass-through pricing assumption for TLX250-CDx to US$5,000 per dose from US$4,500 per dose.

The Overweight rating is retained.

This report was published on June 5, 2023.

Target price is $13.00 Current Price is $11.02 Difference: $1.98
If TLX meets the Wilsons target it will return approximately 18% (excluding dividends, fees and charges).
The company's fiscal year ends in December.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of 11.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 95.00.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 28.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 38.67.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

VIT    VITURA HEALTH LIMITED

Overnight Price: $0.38

Petra Capital rates ((VIT)) as Initiation of coverage with Buy (1) –

Petra Capital initiates coverage of Vitura Health, a technology-led business that has significantly improved the efficiency of the medicinal cannabis supply chain, with a Buy rating and $0.67 target.

The CanView 2 platform connects data between patients, doctors and pharmacists to straddle various administrative hurdles currently slowing the prescription and fulfilment process. Petra Capital expects a considerable increase in operating cash flow over the next three years.

This report was published on June 5, 2023.

Target price is $0.67 Current Price is $0.38 Difference: $0.29
If VIT meets the Petra Capital target it will return approximately 76% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Petra Capital forecasts a full year FY23 dividend of 1.00 cents and EPS of 2.50 cents.
At the last closing share price the estimated dividend yield is 2.63%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.20.

Forecast for FY24:

Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of 3.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.26.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Click to view our Glossary of Financial Terms